Transplant patients with high recurrent Epstein-Barr infection
Conditions
Brief summary
Proportion of patients achieving complete viral clearence after Maribavir therapy
Detailed description
Proportion of patients with a complete elimination of viral replication during the first study phase, Proportion of patients needing a further maribavir course for a significant reduction of viral replication., Rates of EBV recurrence after maribavir withdrawal, Impact of maribavir on the EBV-specific T and B-cell immune response after therapy, Impact on different B-cell subset phenotypes in peripheral blood., Kinetics of viral replication over the course of the anti-viral therapy
Interventions
Sponsors
Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients achieving complete viral clearence after Maribavir therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of patients with a complete elimination of viral replication during the first study phase, Proportion of patients needing a further maribavir course for a significant reduction of viral replication., Rates of EBV recurrence after maribavir withdrawal, Impact of maribavir on the EBV-specific T and B-cell immune response after therapy, Impact on different B-cell subset phenotypes in peripheral blood., Kinetics of viral replication over the course of the anti-viral therapy | — |
Outcome results
None listed